Phase II, multicenter trial of nivolumab (Nivo) and brentuximab vedotin (BV) in patients (Pts) with untreated Hodgkin lymphoma (HL) over the age of 60 years or unable to receive standard ABVD chemotherapy: Results of a study of Academic and Community Cancer Research United (ACCRU) RU051505I. Cheson, B. D., Bartlett, N. L., LaPlant, B., Lee, H., Advani, R. H., Christian, B., Diefenbach, C., Feldman, T., Ansell, S. M. AMER SOC CLINICAL ONCOLOGY. 2020

View details for Web of Science ID 000560368303235